Postpartum depression, or PPD in short, is a serious mood disorder affecting nearly 1 in 7 new mothers, causing intense sadness, anxiety, exhaustion, feelings of worthlessness, and even anger after childbirth (Source: PostpartumDepression.org). While Sage Therapeutics' Zurzuvae is currently the only FDA-approved oral treatment for PPD, conventional therapies like psychotherapy and antidepressants are still widely used off-label.
The stock we are bringing to your attention today is Lipocine Inc. (LPCN), which is developing an oral drug for the treatment of postpartum depression.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com